Literature DB >> 11306680

Transcriptional induction of hepatic NADPH: cytochrome P450 oxidoreductase by thyroid hormone.

H C Li1, D Liu, D J Waxman.   

Abstract

Studies were carried out to elucidate the mechanism whereby thyroid hormone (T3) induces NADPH:cytochrome P450 oxidoreductase (P450R) mRNA in rat liver in vivo. Northern blot analysis revealed that T3 treatment increases unspliced liver nuclear P450R RNA 4-fold within 8 h and that this induction precedes the induction of mature, cytoplasmic P450R RNA. Unspliced nuclear P450R RNA was suppressed below basal levels 24 h after T3 treatment, despite the continued presence of elevated circulating T3 levels. To determine whether the T3-stimulated increase in nuclear P450R RNA reflects an increase in P450R transcription initiation, nuclear run-on transcription assays were carried out. T3 induced a 6- to 8-fold increase in P450R transcription rate within 12 h, sufficient to account for the observed increase in nuclear P450R precursor RNA, followed by a decrease back to basal transcription levels at 24 h, consistent with the nuclear RNA profile. Similar transcriptional increases were observed in nuclear run-on transcription studies using hybridization probes corresponding to nine different fragments of the P450R gene, spanning exon 2 to exon 16. Thus, P450R transcription initiation, not transcription elongation, is the T3-regulated event. Similar results were obtained during short (5 min) compared with long (45 min) nuclear run-on transcription assays, suggesting that changes in nuclear RNA processing or regulated degradation do not contribute to the overall RNA induction. This finding was confirmed by the ability of the RNA polymerase inhibitor actinomycin D, administered in vivo, to block T3 induction of P450R transcriptional activity. We conclude that P450R transcription, rather than nuclear RNA processing or mRNA stabilization, is the primary mechanism whereby T3 induces hepatic P450R mRNA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11306680     DOI: 10.1124/mol.59.5.987

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  4 in total

1.  Consequences of POR mutations and polymorphisms.

Authors:  Walter L Miller; Vishal Agrawal; Duanpen Sandee; Meng Kian Tee; Ningwu Huang; Ji Ha Choi; Kari Morrissey; Kathleen M Giacomini
Journal:  Mol Cell Endocrinol       Date:  2010-11-09       Impact factor: 4.102

2.  Transcriptional regulation of the human P450 oxidoreductase gene: hormonal regulation and influence of promoter polymorphisms.

Authors:  Meng Kian Tee; Ningwu Huang; Izabella Damm; Walter L Miller
Journal:  Mol Endocrinol       Date:  2011-03-10

3.  The redox imbalance and the reduction of contractile protein content in rat hearts administered with L-thyroxine and Doxorubicin.

Authors:  Agnieszka Korga; Jaroslaw Dudka; Franciszek Burdan; Justyna Sliwinska; Slawomir Mandziuk; Katarzyna Dawidek-Pietryka
Journal:  Oxid Med Cell Longev       Date:  2012-02-26       Impact factor: 6.543

4.  Intensification of doxorubicin-related oxidative stress in the heart by hypothyroidism is not related to the expression of cytochrome P450 NADPH-reductase and inducible nitric oxide synthase, as well as activity of xanthine oxidase.

Authors:  Jaroslaw Dudka; Franciszek Burdan; Agnieszka Korga; Magdalena Iwan; Barbara Madej-Czerwonka; Monika Cendrowska-Pinkosz; Agnieszka Korobowicz-Markiewicz; Barbara Jodlowska-Jedrych; Wlodzimierz Matysiak
Journal:  Oxid Med Cell Longev       Date:  2012-08-23       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.